Immune Spatial Features of Guselkumab Cutaneous Response

Recruiting now · Phase 4

Conditions studied: Psoriasis of Scalp

In brief

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Key facts

Study ID

NCT05858632

Run by

University of California, San Francisco

People needed

10

Starts

2023-07-01

Expected to finish

2028-06-30

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• taking systemic immunosuppressives in the last 4 weeks
• pregnancy
• severe immunodeficiency (either from genetic or infectious causes).
• tuberculosis or other active serious infection
• active systemic malignancy.
• breast-feeding
• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
• Males who are trying to conceive

Where it is running

• University of California San Francisco — San Francisco, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.